Approval · Notice of Compliance 888 · 2002
ADVAIR DISKUS: Notice of Compliance 888
Issued March 1, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 888
- Date
- March 1, 2002
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: for the maintenance treatment of asthma in patients with reversible obstructive airways disease where the use of a combination product is considered to be appropriate
- Therapeutic class
- Bronchodilator and corticosteroid for oral inhalation
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ADVAIR DISKUS | Not yet assigned | — |
| ADVAIR | Not yet assigned | — |
Medicinal ingredients
- FLUTICASONE PROPIONATE 100 MCG per PCK
- SALMETEROL XINAFOATE 50 MCG per PCK
- FLUTICASONE PROPIONATE 250 MCG per PCK
- FLUTICASONE PROPIONATE 500 MCG per PCK
- FLUTICASONE PROPIONATE 50 MCG per ACT
- SALMETEROL XINAFOATE 25 MCG per ACT
- FLUTICASONE PROPIONATE 125 MCG per ACT
- FLUTICASONE PROPIONATE 250 MCG per ACT